Skip to main content
All lobbying filings

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. filed a Q1 report for Alnylam Pharmaceuticals, Inc. on April 21, 2025.

Lobbying for Alnylam Pharmaceuticals, Inc. · Pharmaceutical manufacturer

As filed: ALNYLAM PHARMACEUTICALS, INC. for ALNYLAM PHARMACEUTICALS, INC.

All filings by Alnylam Pharmaceuticals, Inc. · Everything Alnylam Pharmaceuticals, Inc. has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 21, 2025
Expenses
$440,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Massachusetts

Official filing document

 Lobbyists on this filing 1
  • CURTIS RHYNE
    Previously held: Rep. Virginia Foxx (2008-2009), House Republican Study Committee (2009-2014), Rep. Richard Hudson (2014-2017), Rep. George Holding (2017-2020)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2

Issues related to Medicare coverage of home infusion; issues related to the implementation of the Inflation Reduction Act.

Issues related to veterans healthcare.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem